HWHong Wang

Hong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hong Wang has a total of 77 co-authors. Here are the top co-authors by number of shared publications:

  • Hui-Fang Xu

    Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, Zhengzhou, China

    3 shared publications
  • Shaokai Zhang

    Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China

    3 shared publications
  • Xiaoyang Wang

    Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

    3 shared publications
  • Xin Wang

    Shanghai Health Development Research Centre, Shanghai, China

    3 shared publications
  • Chunya Liu

    Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China

    2 shared publications
  • Ju-Fang Shi

    Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

    2 shared publications

Latest Publications

  • Open Access

    Assessment of Factors and Trends Affecting Different Pathological Types of Cervical Cancer in China From 2013 to 2022

    by Yufei Li, Runhua Li, Rufei Duan, Xiaofen Gu, Jia You, Hong Wang, Tingting Zuo, Zhe Wang, Weizhao Lin, Li Li, et al.

    Objective: Cervical cancer poses a significant burden globally, particularly in developing countries, with China accounting for 20% of the global incidence. This study aimed to examine temporal changes in the pathological distribution of cervical cancer, particularly squamous cell carcinoma (SCC) and adenocarcinoma (ADC), in China from 2013 to 2022. Methods: A nationwide, multicenter, retrospective study analyzed 6645 cervical cancer cases diagnosed between 2013 and 2022 across seven tertiary hospitals in China. The study analyzed demographic, obstetric, and reproductive factors to identify trends in the proportions of SCC and ADC. Multivariable logistic regression was further performed among women with SCC or ADC to identify factors independently associated with histological type. Results: SCC accounted for 86.9% and ADC for 10.4% of invasive cervical cancer (ICC) cases. Although no significant change in SCC proportion was observed overall, declines were observed in specific subgroups—unemployed women, premenopausal women, and those with a history of reproductive system disease ( p trend = 0.012, 0.021, and 0.011, respectively). In multivariable analysis, compared with Central China, the odds of ADC relative to SCC were significantly higher in North China, Southwest China, East China, and South China, whereas menopausal women, Uyghur women, and rural residents showed lower odds of ADC relative to SCC. Conclusions: Although the overall proportion of SCC among ICC cases remained statistically stable during 2013–2022, SCC showed a decreasing trend in several high‐risk subpopulations. Compared with our 2005–2010 series, the present 2013–2022 study showed a higher ADC proportion and a lower SCC proportion. These findings suggest a gradual shift in the pathological landscape of ICC in China and provide up‐to‐date nationwide multicenter data that may help refine future screening and prevention strategies.

  • Integrated Analysis of Metabolomics and Proteomics Reveals the Potential Mechanism of Lung Injury Induced by Di(2‐Ethylhexyl) Phthalate

    by Siya Wu, Boxiang Wang, Ning Zhang, Chenxi Feng, Hong Wang, Qiaoqiao Zheng, Ruihua Kang, Xuan Niu, Xiaoyang Wang, Xiaoli Guo, et al.

    Di(2‐ethylhexyl) phthalate (DEHP) has been widely detected in environmental compartments and is highly carcinogenic to humans, but the toxic effects of DEHP on lung injury and its mechanisms are still not clear. Herein, the effects of lung injury were evaluated both in vivo and in vitro; meanwhile, the metabolomics and proteomics methodologies were employed to elucidate the intracellular mechanisms of BEAS‐2B cells. The results showed that MEHP treatment significantly decreased cell viability and caused inflammation and fibrosis changes in vivo and in vitro, manifested as abnormal expression of associated genes. There were 26 upregulated and 8 downregulated metabolites found in BEAS‐2B cells exposed to MEHP, which mainly focused on fatty acid metabolism pathways. In addition, the tricarboxylic acid (TCA) cycle, alanine, aspartate, and glutamate metabolism, purine metabolism, butanoate metabolism, and ribosome synthesis are also important events in DEHP pathophysiology. Furthermore, proteomics methodologies and correlation analysis show that PLIN2 and HMGCS1 may be involved in the fatty acid synthesis pathway. These results expand the existing understanding of the molecular basis of DEHP‐induced lung injury and progression, offering a new perspective for exploring its pathological mechanisms.

  • Changes in quality of life in colorectal cancer screening: A multicentre trial in populations in China

    by Xin-Yi Zhou, Yan-Jie Li, Hong Wang, Sen-Yao Cai, Xin Wang, Su-Yang Zou, Lingbin Du, Xianzhen Liao, Donghua Wei, Dong Dong, et al.

    Objective: Evidence is scarce about whether colorectal cancer screening can affect the quality of life of participants, particularly in terms of novel screening strategies in Eastern populations. Methods: From 2018 to 2021, the TARGET-C trial randomly allocated 19,373 participants to one of three screening strategies: (A) one-time colonoscopy; (B) annual faecal immunochemical test with positives referred for colonoscopy; and (C) annual risk-adapted screening with low-risk participants referred for faecal immunochemical test and high-risk participants referred for colonoscopy. Two rounds of follow-up after baseline screening were conducted over the 3-year period. Based on the TARGET-C, a EuroQol five-dimensional questionnaire-based quality of life survey was administrated to the participants, and utility scores and related changes were used as the main outcomes. Results: Taking by-strategy utility scores for participants before being screened at baseline as the comparators ( n = 2921), the changes in utility scores after baseline screening were −0.008 ( P < 0.050) for strategy A, 0.006 ( P < 0.050) for strategy B and 0.000 ( P > 0.050) for strategy C, and the overall difference in quality of life changes among the three strategies was significant ( P < 0.001). Taking the same comparators as above, the changes in utility scores for participants in the second round of follow-up ( n = 9201) were 0.011 ( P < 0.050), 0.011 ( P < 0.050) and 0.005 ( P < 0.050), respectively, and the overall difference was neither clinically meaningful nor statistically significant ( P = 0.113). Conclusions: None of the three colorectal cancer screening strategies had a major effect on the participants’ quality of life over the 3 years. Within one round of screening, incorporating risk-adapted screening and/or faecal immunochemical test might offset the quality of life impact from colonoscopy screening.

  • Open Access

    HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China

    by Jiangong Zhang, Hong Wang, Yin Liu, Zhifang Li, Xiangxian Feng, Xiping Luo, Wen Chen, Shaokai Zhang, Hui Yang, Youlin Qiao

    To evaluate the clinical performance of Hybribio’s 14-type HPV real-time PCR with 16/18 genotyping (HBRT-H14) and its risk stratification utility among women with normal cytology (NILM). From 2017 to 2020, a multicenter cohort enrolled 8,401 women aged 30–64 years with NILM cytology. Baseline HPV testing used HBRT-H14. Women positive for HPV 16/18 were referred for colposcopy; follow-up was annual for 3 years or until the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Analyses included 6,679 women who completed follow-up. Overall HPV positivity was 11.4%, including 2.3% HPV 16/18. Over 3 years, sensitivity and specificity of HPV positivity for CIN2+ were 92.3% (95% confidence interval [CI]: 84.2–96.4) and 89.6% (88.8–90.3). For HPV 16/18 positivity, sensitivity and specificity were 41.0% (30.8–52.1) and 98.2% (97.8–98.5). Three-year cumulative CIN2+ risk was 20.9% (15.2–28.1) for HPV 16/18-positive women, 6.6% (4.9–8.9) for other types, and 0.1% (0.04–0.2) for HPV-negative women. HBRT-H14 shows strong clinical performance for detecting CIN2+, and HPV 16/18 genotyping provides effective risk stratification among women with NILM cytology. Findings support integration of HBRT-H14 into HPV-based screening pathways with HPV 16/18 genotyping and cytology triage of other types. IMPORTANCE: This multicenter prospective study evaluated the Hybribio 14 high-risk HPV real-time PCR assay (HBRT-H14) in 8,401 women with normal (NILM) cytology under guideline-based follow-up. The assay showed high clinical sensitivity and a very low risk among HPV-negative women, and HPV 16/18 genotyping provided clear risk stratification. These findings deliver large-scale, practice-oriented evidence supporting integration of HBRT-H14 into HPV-based screening pathways that use HPV 16/18 genotyping with cytology triage of other types.

  • Open Access

    Lifetime risk of developing and dying from cancer in Henan Province, China: current status, temporal trends, and disparities

    by Qiong Chen, Shuzheng Liu, Yin Liu, Hongwei Liu, Hong Wang, Lanwei Guo, Huifang Xu, Xiaoli Guo, Xiaoyang Wang, Ruihua Kang, et al.


  • Open Access

    Disability-adjusted life years for colorectal cancer in China, 2017-2030: a prevalence-based analysis focusing on the impact of screening coverage and application of local weights (Preprint)

    by Yu Jie Wu, Yan Jie Li, Xin Wang, Xin Yi Zhou, Xin Xin Yan, Hong Wang, Juan Zhu, WanQing Chen, Ju Fang Shi

    BACKGROUND Most studies evaluated disability-adjusted life years (DALYs) of colorectal cancer (CRC) based on a set of generic disability weights (DWs), while this study aimed to apply local CRC-stage-specific DWs to estimate CRC-DALYs value in Chinese populations and considered the influence of local screening coverage of CRC. OBJECTIVE This study aimed to estimate CRC-DALYs in 2017 and predict CRC-DALYs in 2030 by local DWs of the clinical stage(I-IV) from the Chinese study, and also took into account the influence of changes of local screening coverage of CRC. METHODS A prevalence-based model was constructed using data from various sources. Years lived with disability (YLDs) were mainly estimated using cumulative prevalence data (based on CRC incidence rates, population number, and survival rates), stage-specific proportions of CRC, and DWs of the local population. Years of life lost (YLLs) were calculated by the CRC mortality rates and standard life expectancies. Annual percent change (APC) from Joinpoint analyses was obtained to estimate CRC prevalence and mortality rates to 2030, and then to predict the DALYs for 2020, 2025, and 2030. Main assumptions were made for CRC screening coverage. Sensitivity analysis was used to assess the impact of population, DWs, and screening coverage on the results. RESULTS In Chinese populations in 2017, the estimated CRC-DALYs value was 4,303.3 thousand (11.8% for YLDs). If the CRC screening coverage in China (2.3%) remains unchanged, the overall DALYs in 2030 are predicted to increase by 37.2% (45.1% occurred to those aged 65+ years). More optimistically, the DALYs would then decrease by 0.7% in 2030 (from 5,902.5 thousand to 5,860.2 thousand) if the coverage rate can be increased to 25.0%. Sensitivity analysis showed that using local DWs would change the base-case values by ~5.7%. CONCLUSIONS Estimated CRC-DALYs in China using population-specific DWs were considerably lower (with a higher percentage of YLDs) than the GBD estimates (5,865.0 thousand, of 4.6% for YLDs), suggesting the impact of applying local parameters. Sustainable scale-up CRC screening needs to be in place to moderate the growth trend of CRC-DALYs in China.

  • Open Access

    Estimating the economic burden of colorectal cancer in China, 2019–2030: A population‐level prevalence‐based analysis

    by Hong Wang, Yan‐Jie Li, Lin Lei, Cheng‐Cheng Liu, Wan‐Qing Chen, Min Dai, Xin Wang, Jie‐Bin Lew, Ju‐Fang Shi, Ni Li, et al.

    Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Comprehensive data on the economic burden of CRC at a population‐level is critical in informing policymaking, but such data are currently limited in China.Methods: From a societal perspective, the economic burden of CRC in 2019 was estimated, including direct medical and nonmedical expenditure, disability, and premature‐death‐related indirect expenditure. Data on disease burden was taken from the GBD 2019 and analyzed using a prevalence‐based approach. The per‐person direct expenditure and work loss days were from a multicenter study; the premature‐death‐related expenditure was estimated using a human capital approach. Projections were conducted in different simulated scenarios. All expenditure data were in Chinese Yuan (CNY) and discounted to 2019.Results: In 2019, the estimated overall economic burden of CRC in China was CNY170.5 billion (0.189% of the local GDP). The direct expenditure was CNY106.4 billion (62.4% of the total economic burden), 91.4% of which was a direct medical expenditure. The indirect expenditure was CNY64.1 billion, of which 63.7% was related to premature death. The predicted burden would reach CNY560.0 billion in 2030 given constant trends for disease burden; however, it would be alternatively reduced to <CNY515.2 billion if the cancer prevention and control goals set by the United Nations and China for 2030 are achieved.Conclusions: The population‐level economic burden of CRC in China in 2019 seemed noteworthy, with the direct expenditure accounting for more than half. Without effectively reducing exposure to modifiable factors and expanding screening coverage, the burden would continue increasing.


  • Open Access

    Hepatitis C Knowledge and Self-Reported Testing Behavior in the General Population in China: Online Cross-Sectional Survey

    by Yin Liu, Juan Su, Xiaoyang Wang, Huifang Xu, Hong Wang, Ruihua Kang, Liyang Zheng, Yixian Wang, Chunya Liu, Yiping Jing, et al.

    Background: The World Health Organization has proposed a worldwide target of eliminating hepatitis C virus (HCV) by 2030. A better understanding of HCV, testing behaviors, and associated factors in the general population is essential. Objective: This study aimed to assess HCV knowledge, self-reported HCV testing behavior, and willingness to undergo HCV screening in the general Chinese population. Methods: A cross-sectional online survey of the general Chinese population aged ≥15 years was conducted from November 2021 to May 2023. Participant characteristics were assessed based on their knowledge level and uptake of HCV testing. Participants ever having heard of HCV were recognized as being aware of HCV and asked additional HCV knowledge questions using a brief, validated 9-item scale. Participants with 0-3 points and who were unaware of HCV were categorized as having poor knowledge, and those with 4-6 points and 7 points were categorized as having fair and good knowledge, respectively. Participant uptake of HCV testing, testing results, reasons for undergoing or not undergoing HCV testing, and willingness to undergo HCV screening were collected through self-reports. Ordinal and binary logistic regression analyses were used to assess factors associated with the HCV knowledge level and the uptake of HCV testing, respectively. Results: A total of 1491 valid participants’ questionnaires were included. Of these, 714 (47.6%) participants were aware of HCV. The proportion of participants with poor, fair, and good HCV knowledge was 63.4% (945/1491), 9.3% (139/1491), and 27.3% (407/1491), respectively. A total of 465 (31.2%) participants reported ever undergoing HCV testing, and 4 (0.9%) were anti-HCV antibody positive. Most participants were tested for HCV following blood donation (353/465, 75.9%). The most common reasons for not undergoing HCV screening were a lack of HCV awareness (665/1026, 64.8%), followed by a low self-perceived risk of infection (176/1026, 17.2%). Of 1026 participants who had never undergone HCV testing, 937 (91.3%) were willing to undergo HCV screening if universal screening was provided at no cost. The HCV knowledge level was positively associated with the HCV testing rate. Participants who were less educated, lived in rural areas, resided in West China, and were currently alcohol drinkers had lower HCV knowledge and reduced odds of having undergone HCV testing. In contrast, participants with a blood donation history and a family history of hepatitis B virus or HCV infection had higher HCV knowledge and increased odds of prior testing. Participants aged ≥60 years had lower knowledge, and women had reduced odds of having undergone previous HCV testing. Conclusions: The general population of China has low HCV knowledge and testing rate. There is an urgent need for enhanced HCV awareness and scaled-up HCV screening and treatment. Individuals who are less well educated, reside in less-developed areas, currently drink alcohol, and are female should be prioritized for health education and interventions.


  • Open Access

    Hepatitis C Knowledge and Self-Reported Testing Behavior in the General Population in China: Online Cross-Sectional Survey (Preprint)

    by Yin Liu, Juan Su, Xiaoyang Wang, Huifang Xu, Hong Wang, Ruihua Kang, Liyang Zheng, Yixian Wang, Chunya Liu, Yiping Jing, et al.

    BACKGROUND The World Health Organization has proposed a worldwide target of eliminating hepatitis C virus (HCV) by 2030. A better understanding of HCV, testing behaviors, and associated factors in the general population is essential. OBJECTIVE This study aimed to assess HCV knowledge, self-reported HCV testing behavior, and willingness to undergo HCV screening in the general Chinese population. METHODS A cross-sectional online survey of the general Chinese population aged ≥15 years was conducted from November 2021 to May 2023. Participant characteristics were assessed based on their knowledge level and uptake of HCV testing. Participants ever having heard of HCV were recognized as being aware of HCV and asked additional HCV knowledge questions using a brief, validated 9-item scale. Participants with 0-3 points and who were unaware of HCV were categorized as having poor knowledge, and those with 4-6 points and 7 points were categorized as having fair and good knowledge, respectively. Participant uptake of HCV testing, testing results, reasons for undergoing or not undergoing HCV testing, and willingness to undergo HCV screening were collected through self-reports. Ordinal and binary logistic regression analyses were used to assess factors associated with the HCV knowledge level and the uptake of HCV testing, respectively. RESULTS A total of 1491 valid participants’ questionnaires were included. Of these, 714 (47.6%) participants were aware of HCV. The proportion of participants with poor, fair, and good HCV knowledge was 63.4% (945/1491), 9.3% (139/1491), and 27.3% (407/1491), respectively. A total of 465 (31.2%) participants reported ever undergoing HCV testing, and 4 (0.9%) were anti-HCV antibody positive. Most participants were tested for HCV following blood donation (353/465, 75.9%). The most common reasons for not undergoing HCV screening were a lack of HCV awareness (665/1026, 64.8%), followed by a low self-perceived risk of infection (176/1026, 17.2%). Of 1026 participants who had never undergone HCV testing, 937 (91.3%) were willing to undergo HCV screening if universal screening was provided at no cost. The HCV knowledge level was positively associated with the HCV testing rate. Participants who were less educated, lived in rural areas, resided in West China, and were currently alcohol drinkers had lower HCV knowledge and reduced odds of having undergone HCV testing. In contrast, participants with a blood donation history and a family history of hepatitis B virus or HCV infection had higher HCV knowledge and increased odds of prior testing. Participants aged ≥60 years had lower knowledge, and women had reduced odds of having undergone previous HCV testing. CONCLUSIONS The general population of China has low HCV knowledge and testing rate. There is an urgent need for enhanced HCV awareness and scaled-up HCV screening and treatment. Individuals who are less well educated, reside in less-developed areas, currently drink alcohol, and are female should be prioritized for health education and interventions.